Trial Profile
Phase II Study of Maintenance Therapy With Decitabine (NSC 127716, IND 50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML less than 60 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Busulfan; Cytarabine; Daunorubicin; Etoposide; Filgrastim
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov. (NCT01647074)
- 19 Jul 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov. (NCT01647074)